Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.

Autor: Havele SA; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Khurana MC; Section of Dermatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA., McMahon P; Section of Dermatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Murthy AS; Section of Dermatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Perman MJ; Section of Dermatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Treat JR; Section of Dermatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2022 Mar; Vol. 39 (2), pp. 291-294.
DOI: 10.1111/pde.14980
Abstrakt: Dupilumab is a fully humanized monoclonal antibody that suppresses Th2-mediated inflammation by inhibiting signaling of interleukin-4 and interleukin-13 through the interleukin-4 alpha receptor subunit, and is approved by the FDA for the treatment of moderate to severe atopic dermatitis (AD) in children 6 years of age and older. While initial data from phase 2 trials in children less than 6 years are promising, dupilumab use in children less than 6 months of age is not well studied. Here we present a case of a 5-month-old boy with severe primary AD, eosinophilia, hypogammaglobulinemia, and poor weight gain, who was successfully treated with dupilumab and experienced no serious adverse effects. To our knowledge, this is the youngest patient to receive dupilumab to date.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: